Pharmacologic basis for the treatment of tinea capitis

Pediatric Infectious Disease Journal

Volumn 18, Issue 2, 1999, Pages 191-199

  Blumer, Jeffrey L ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Allylamine; Antifungal agent; Azole; Cytochrome P 450; Dermatophyte; Fluconazole; Griseofulvin; Itraconazole; Ketoconazole; Pharmaco kinetics; Stratum corneum; Terbinafine; Tinea capitis; Triazole; Trichophyton

Indexed keywords

FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

CONFERENCE PAPER; DRUG DISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN TOXICITY; TINEA CAPITIS;

EID: 0033023426     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199902000-00027     Document Type: Conference Paper

References (37)

1. Schwartz RA, Janniger CK. Tinea capitis. Cutis 1995;55:29-33.
2. Abdel-Rahman SM, Nahata MC. Treatment of tinea capitis. Ann Pharmacother 1997;31:338-48.
3. Fitzpatirck RE, Newcomer VD. Dermatophytosis and candidiasis. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. Philadelphia: Saunders, 1992;782-814.
4. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995;8:240-59.
5. Williams JV, Honig PJ, McGinley KJ, Leyden JJ. Semiquantitative study of tinea capitis and the asymptomatic carrier state in inner-city school children. Pediatrics 1995;96:265-7.
6. Sharma V, Hall JC, Knapp JF, Sarai S, Galloway D, Babel DE. Scalp colonization by Trichophyton tonsurans in an urban pediatric clinic. Arch Dermatol 1988;124:1511-13.
7. Babel DE, Baughman SA. Evaluation of the adult carrier state in juvenile tinea capitis caused by Trichophyton tonsurans. J Am Acad Dermatol 1989;21:1209-12.
8. Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994;31:S21-5.
9. Roberts SOB. Treatment of the superficial and subcutaneous mycoses. In: Spellar DCE, ed. Antifungal chemotherapy. New York: Wiley, 1980;225-83.
10. Elewski BE, Hazen PG. The superficial mycoses and the dermatophytes. J Am Acad Dermatol 1989;21:655-73.
11. Davis RR. Griseofulvin. In: Spellar DCE, ed. Antifungal chemotherapy. New York: Wiley, 1980;149-82.
12. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs 1996;52:209-24.
13. Araujo OE, Flowers FP, King MM. Griseofulvin: a new look at an old drug. DICP 1990;24:851-4.
14. Albengres E, Le Louët H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Safety 1998;18:83-97.
15. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992;43:259-84.
16. 6Cl, a metabolic product of Penicillium griseofulvum Dierckx. Biochem J 1939;33:240-8.
17. Gentles JC. Experimental ringworm in guinea pigs: oral treatment with griseofulvin. Nature 1958;182:476-7.
18. Becker LE. Griseofulvin. Dermatol Clin 1984;2:115-20.
19. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part 1. J Am Acad Dermatol 1994;30:677-98.
20. Shah VP, Epstein WL, Riegelman S. Role of sweat in accumulation of orally administered griseofulvin in skin. J Clin Invest 1974;53:1673-8.
21. Hatzis J, Tosca A, Varelzidis A, Stratigos J. The role of sweat in the pharmacokinetics of ketoconazole and griseofulvin. Br J Dermatol 1987;117:797-800.
22. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34.
23. Schäfer-Korting M, Korting HC, Dorn M, Mutschler E. Ketoconazole concentrations in human skin blister fluid and plasma. Int J Clin Pharmacol Ther Toxicol 1984;22:371-4.
24. Harris R, Jones HE, Artis WM. Orally administered ketoconazole: route of delivery to the human stratum corneum. Antimicrob Agents Chemother 1983;24:876-82.
25. Artis WM. Final pathway for delivery of oral antifungals to keratinized cornified skin. In: Meinhof W, ed. Oral therapy in dermatomycoses: a step forward. Oxford, UK: Medical Education Services, 1985:61-70.
26. Lewis JH, Zimmerman HJ, Benson GD, Ishak G. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology 1984;86:503-13.
27. Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996;51: 585-620.
28. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994;30:911-33.
29. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988;18:263-8.
30. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993;37:778-84.
31. Degreef HJ, DeDoncker PRG. Current therapy of dermatophytosis. J Am Acad Dermatol 1994;31:S25-30.
32. Nahata MC, Brady MT. Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection. Eur J Clin Pharmacol 1995;48:291-93.
33. Leyden J. Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol 1998;38:S42-7.
34. Faergemann J, Zehender H, Jones T, Maibach I. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Dermatol Venereol (Stockh) 1990;71:322-6.
35. Faergemann J, Zehender H, Denouël J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Dermatol Venereol (Stockh) 1993;73:305-9.
36. Nejjam F, Zagula M, Cabiac MD, Guessous N, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol 1995;132:98-105.
37. Jones TC. Overview of the use of terbinafine (Lamisil) in children. Br J Dermatol 1995;132:683-9.